Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00682851 · ClinicalTrials.gov registry record
A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test
A clinical trial of Bacterial Vaginosis and Urogenital Infection by Trichomonas Vaginalis, sponsored by University of Pittsburgh.
- Completed
- Registry status
- 519
- Enrollment target
- 1
- Study location
NCT00682851: Completed study of Bacterial Vaginosis and Urogenital Infection by Trichomonas Vaginalis, sponsored by University of Pittsburgh.
NCT00682851 is a study of Bacterial Vaginosis and Urogenital Infection by Trichomonas Vaginalis that has completed, run by University of Pittsburgh. The registered enrollment target is 519 participants, above the 304-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00682851, a study of Bacterial Vaginosis and Urogenital Infection by Trichomonas Vaginalis, has completed, sponsored by University of Pittsburgh.
- COMPLETED
- Registry status
- 519 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to see if two rapid bedside tests (OSOM Trichomonas Rapid Test and BVBlue Test) that give results in 10 minutes are as accurate as standard tests to diagnose common vaginal infections.
Primary Outcome
Sensitivity of the OSOM Rapid test and PCR wet mount microscopy in diagnosing Trichomonas vaginalis using Trichomonas culture as the gold standard in symptomatic and asymptomatic women. The sensitivity of a test is the percentage of people who have the infection (as diagnosed by the gold standard method) among those who have a positive test.
Conditions Studied
Interventions
- DEVICE OSOM Trichomonas Rapid Test
- DEVICE OSOM BVBlue Test
Study Locations (1)
Pennsylvania
- Magee-Womens Hospital of UPMC - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 519 participants |
| Start Date | 2008-07 |
| Est. Completion | 2009-04 |
What the finished NCT00682851 record still lists
NCT00682851 is an observational study that tracks outcomes without assigning an intervention. The registered 519 participants enrollment target is mid-sized for trials with a published cap, above the 304-participant average among 15 other Bacterial Vaginosis trials with a reported enrollment target (71% higher).
The record links to 2 conditions, with Bacterial Vaginosis appearing as the primary indexed condition, and to 2 interventions - of which OSOM Trichomonas Rapid Test is the first listed.
NCT00682851 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00682851 about?
NCT00682851 is a clinical study titled "A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test". This research is being done to see if two rapid bedside tests (OSOM Trichomonas Rapid Test and BVBlue Test) that give results in 10 minutes are as accurate as standard tests to diagnose common vaginal infections.
What is the current status of trial NCT00682851?
This trial is currently completed. The enrollment target is 519 participants. The study started on 2008-07. Estimated completion is 2009-04.
What conditions does trial NCT00682851 study?
This clinical trial studies the following conditions: Bacterial Vaginosis, Urogenital Infection by Trichomonas Vaginalis.
What interventions are being tested in trial NCT00682851?
The interventions under investigation include: OSOM Trichomonas Rapid Test (DEVICE), OSOM BVBlue Test (DEVICE).
Who is sponsoring clinical trial NCT00682851?
This trial is sponsored by University of Pittsburgh, which has 1,238 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00682851 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bacterial Vaginosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00682851's enrollment target sits among peer trials
519 6th of 15 higher than 10 of 15 other Bacterial Vaginosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bacterial Vaginosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Clinical Protocol CERN Feasibility Study
RECRUITING · NA
-
Prospective Data Bank Creation to Study Vaginal Conditions
RECRUITING
-
Exploring the Effects of an Intravaginal Lactic Acid Gel on the Vaginal Microbiome
RECRUITING · Early Phase 1
-
Single Arm Trial of Menstrual Cups Among Economically Vulnerable Women to Reduce Bacterial Vaginosis and STIs
ACTIVE NOT RECRUITING · Phase 2
-
Treatment of Bacterial Vaginosis (BV) With Tinidazole
COMPLETED · Phase 4
-
Performance Study of the Cobas® BV/CV Test on Samples From Participants With and Without Symptoms of Bacterial Vaginosis and Candida Vaginitis
COMPLETED
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia